KINETA INC (KA)

US49461C1027 - Common Stock

0.452  -0.03 (-7.19%)

After market: 0.4595 +0.01 (+1.66%)

News Image
4 days ago - InvestorPlace

KA Stock Earnings: Kineta Misses EPS for Q1 2024

KA stock results show that Kineta missed analyst estimates for earnings per share the first quarter of 2024.

News Image
4 days ago - BusinessInsider

KA Stock Earnings: Kineta Misses EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kineta (NASDAQ:KA) just reported results for the first quarter of 2024.Kineta r...

News Image
4 days ago - Kineta, Inc.

Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety...

News Image
a month ago - Kineta, Inc.

Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts

News Image
2 months ago - BusinessInsider

KA Stock Earnings: Kineta Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kineta (NASDAQ:KA) just reported results for the fourth quarter of 2023.Kineta ...

News Image
2 months ago - InvestorPlace

KA Stock Earnings: Kineta Beats EPS for Q4 2023

KA stock results show that Kineta beat analyst estimates for earnings per share the fourth quarter of 2023.

News Image
2 months ago - Kineta, Inc.

Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts in the VISTA-101 trial No...

News Image
3 months ago - InvestorPlace

Today‚Äôs Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Pre-market stock movers are worth checking on Friday as investors prepare for the last day of trading this week with all of the latest news!

News Image
3 months ago - Seeking Alpha

Kineta stock falls ~25.7% after co cuts workforce by 64%, including CEO (NASDAQ:KA)

Kineta is slashing its workforce by 64% and terminating enrollment in a clinical trial, causing shares to plummet 25.66%.

News Image
3 months ago - Kineta, Inc.

Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium

SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel...

News Image
3 months ago - Kineta, Inc.

Kineta to Present at Upcoming Investor Conferences

SEATTLE, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel...

News Image
3 months ago - Kineta, Inc.

Kineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat Series

SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel...

News Image
4 months ago - Kineta, Inc.

Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors

Cleared First Four Monotherapy Doses and Initial Combination Cohort with No Dose Limiting Toxicities at any Dose Level KVA12123 Monotherapy...

News Image
5 months ago - Kineta, Inc.

Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event

SEATTLE, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel...

News Image
5 months ago - Virtual Investor Conferences

Life Science Investor Forum: Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

News Image
5 months ago - Kineta, Inc.

Kineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for Cancer

VISTA Blocking KVA12123 Monoclonal Antibody (mAb) Engineered to Provide Strong Single Agent Anti-Tumor Activity While Minimizing Cytokine Related Adverse...

News Image
5 months ago - Virtual Investor Conferences

Kineta to Present at the Life Sciences Investor Forum December 14th

Company invites individual and institutional investors, as well as advisors and analysts, to attend in person or online at VirtualInvestorConferences.com